DoW Lung Cancer Translational Research Award

About this funding opportunity

Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Translational Research Award (TRA) supports advanced translational research that will foster transformation of promising ideas in lung cancer into clinical applications. Research must address at least one of the FY26 LCRP areas of emphasis.

Distinctive Features: This funding mechanism intends to support a broad range of translational studies and allows application submission under: Funding Level 1, Advanced/late-stage preclinical work or correlative studies; or Funding Level 2, Pilot clinical trials of novel interventions.

Topic areas: General and Cross-cutting R&D, Life Sciences and Health.

Funding amount

This grant provides Varies in funding.

Deadline

Applications are due Sep 02, 2026. Confirm the exact closing time on the official program page before applying.

Who can apply

This opportunity is open to the following applicant types:

• Open to all applicant types

Eligibility

The program did not publish a separate eligibility statement. See the official opportunity page for the full eligibility criteria.

Agency

DoW Lung Cancer Translational Research Award is administered by Defense Health Agency Contracting Activity - DHACA (AMRAA), listed via Grants.gov.